⌕
Castle Biosciences · CSTL · Nasdaq
Tenet 55 · Mixed
Compare
$32.98+0.70%At closeTenet 55 · Mixed
$32.98+0.23 (+0.70%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Castle Biosciences (CSTL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~38.3%/yr (FY21→FY25), net margin −7.0%. Worth your attention in FY25: Share count (+15.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3.7%
344.2
FY21→FY25CAGR +38.3%/yr
Net income ($M)—
−24.2
one-off year: see footnoteCAGR —
Free cash flow ($M)▼22.5%
28.3
FY21→FY25CAGR —
Diluted EPS—
−0.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+15.3%

25.1mn → 29.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$36.0M

+27.2% YoY in FY25 · 10.5% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)344.2Revenue−71.0COGS273.2Gross profit−51.9R&D−229.3SG&A−42.8Op income18.7Tax & other−24.2Net income

-7¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 83.2% → 79.4%. Net margin -7.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
377,126.0344,229.0332,069.0219,788.0137,039.094,085.0▲3.7%+38.3%
Cost of revenue
86,467.071,028.060,205.044,982.032,009.015,822.0▲18.0%+45.6%
Gross profit
290,659.0273,201.0271,864.0174,806.0105,030.078,263.0▲0.5%+36.7%
Research & development
58,293.051,850.052,041.053,618.044,903.029,646.0▼0.4%+15.0%
Selling, general & admin
251,544.0229,323.0200,047.0180,152.0143,003.086,738.0▲14.6%+27.5%
Total operating expenses
318,694.0316,011.0263,194.0242,783.0177,885.0118,342.0▲20.1%+27.8%
Operating incomefeeds ROC rank
−28,035.0−42,810.08,670.0−67,977.0−72,855.0−40,079.0——
Other income, net
5,416.013,296.012,894.010,612.03,951.067.0——
Pretax income
−22,619.0−29,514.021,564.0−57,365.0−68,904.0−40,012.0——
Income tax
395.0−5,356.03,319.0101.0−1,766.0−8,720.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−23,014.0−24,158.018,245.0−57,466.0−67,138.0−31,292.0——
Per share
Diluted EPSbuyback-sensitive
−0.75−0.830.62−2.14−2.58−1.24——
Diluted shares (mn)
30.6328.9929.2526.8026.0525.14▼0.9%+3.6%
Margins
Gross margin71st pct in Healthcare
77.1%79.4%81.9%79.5%76.6%83.2%▼2.5pp−3.8pp
Operating margin
−7.4%−12.4%2.6%−30.9%−53.2%−42.6%▼15.0pp+30.2pp
Net margin31st pct in Healthcare
−6.1%−7.0%5.5%−26.1%−49.0%−33.3%▼12.5pp+26.2pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 3% vs a 15% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −0% vs a 15% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Castle Biosciences' revenue last fiscal year?

Castle Biosciences reported revenue of $344.2M in fiscal 2025, up 3.7% from fiscal 2024.

What was Castle Biosciences' net income?

Castle Biosciences reported net income of −$24.2M in fiscal 2025, a net margin of −7.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.